PENNINGTON, N.J. and SAN DIEGO, Nov. 2, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) will host a conference call and webcast for investors and analysts on Friday, November 12 at 7:00 AM ET featuring key opinion leaders (KOLs) Matteo Carlino, MD, from Westmead and Blacktown Hospitals, Adil Daud, MD, from University of California San Francisco, Pablo Fernandez Peñas MD, PhD, FACD, from The University of Sydney, and Montaser Shaheen, MD, from the University of Arizona Cancer Center. The KOLs will discuss the clinical relevance of the updated KEYNOTE-695 data being presented in a poster at the SITC 2021 Annual Meeting. Specifically, the KEYNOTE-695 clinical trial enrolled metastatic melanoma patients that are refractory to Immune Checkpoint Blockade, non-responders as defined by the Society of Immunotherapy of Cancer (SITC) recommendations.¹

Adil Daud, M.D., a Professor of Medicine at The University of California, San Francisco, Director of the Melanoma Clinical Research, remarked, "TAVO works by optimizing cellular uptake of DNA-based IL-12 in the tumor microenvironment, leading to local, sustained production of IL-12 in the tumor, where it matters. TAVO recruits and primes immune cancer-fighting cells in the tumor leading to systemic immune responses without systemic toxicity, and we look forward to the updated data at SITC 2021 in this highly refractory patient population."

To register for the event, please click here.

¹Kluger HM, Tawbi HA, Ascierto ML, et al. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce. Journal for ImmunoTherapy of Cancer 2020;8:e000398. doi:10.1136/ jitc-2019-000398

About OncoSec Medical Incorporated
OncoSec Medical Incorporated (the "Company," "OncoSec," "we" or "our") is a biotechnology company focused on developing cytokine-based intratumoral immunotherapies. OncoSec's lead immunotherapy investigational product – TAVO™ (tavokinogene telseplasmid) – is a DNA plasmid encoding interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions, that is administered by intratumoral injection and electroporation. The technology is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, enabling activation of a systemic tumor-specific immune response to target and attack tumors throughout the body. OncoSec has built a clinical pipeline utilizing TAVO™ in combination with checkpoint inhibitors as a potential treatment for multiple cancer indications, with the goal of addressing a great unmet medical need in oncology: disease resistant to checkpoint inhibitor therapy. Results from clinical studies of In clinical studies, TAVO™, either as monotherapy or in combination with checkpoint inhibitors, has demonstrated induction of a local tumor immune response and a systemic antitumor effect, along with an acceptable safety profile, warranting further development. In addition to TAVO™, OncoSec is identifying and developing new DNA-encoded therapeutic candidates and a visceral lesion applicator, to target deeper visceral lesions, such as liver, lung or pancreatic lesions. For more information, please visit www.oncosec.com.

TAVO™ is a trademark of OncoSec Medical Incorporated.

Risk Factors and Forward-Looking Statements
This release, as well as other information provided from time to time by the Company or its employees, may contain forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Forward-looking statements provide the Company's current beliefs, expectations and intentions regarding future events and involve risks, uncertainties (some of which are beyond the Company's control) and assumptions. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "should," "will" and "would" and similar expressions (including the negative of these terms). Although we believe that expectations reflected in the forward- looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. The Company intends these forward-looking statements to speak only at the time they are published on or as otherwise specified and does not undertake to update or revise these statements as more information becomes available, except as required under federal securities laws and the rules and regulations of the Securities Exchange Commission ("SEC"). In particular, you should be aware that the success and timing of our clinical trials, including safety and efficacy of our product candidates, patient accrual, unexpected or expected safety events, the impact of COVID-19 on the supply of our candidates or the initiation or completion of clinical trials and the usability of data generated from our trials may differ and may not meet our estimated timelines. Please refer to the risk factors and other cautionary statements provided in the Company's Annual Report on Form 10-K for the fiscal year ended July 31, 2020 and subsequent periodic and current reports filed with the SEC (each of which can be found at the SEC's website www.sec.gov), as well as other factors described from time to time in the Company's filings with the SEC.

Company Contact
Investor Contact
Mike Moyer
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/oncosec-medical-hosting-sitc-key-opinion-leader-webinar-on-updated-data-from-the-keynote-695-study-301413873.html

SOURCE OncoSec Medical Incorporated